Kevin K. Brown mainly focuses on Idiopathic pulmonary fibrosis, Pulmonary fibrosis, Internal medicine, Pathology and Surgery. Kevin K. Brown studies Usual interstitial pneumonia, a branch of Idiopathic pulmonary fibrosis. Kevin K. Brown has researched Pulmonary fibrosis in several fields, including Survival rate, Respiratory disease, PEDF and Epidemiology.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Cardiology. His Pathology study combines topics from a wide range of disciplines, such as Endothelial stem cell, Hypersensitivity pneumonitis, Interstitial pneumonia and Interstitial lung disease. His Surgery research is multidisciplinary, relying on both Placebo, FEV1/FVC ratio and Urology.
The scientist’s investigation covers issues in Idiopathic pulmonary fibrosis, Internal medicine, Pathology, Interstitial lung disease and Lung. The various areas that Kevin K. Brown examines in his Idiopathic pulmonary fibrosis study include Pulmonary fibrosis, Physical therapy and Intensive care medicine. His Pulmonary fibrosis study combines topics in areas such as Survival rate, Respiratory disease and Intensive care.
His Internal medicine research incorporates themes from Gastroenterology, Surgery and Cardiology. His research integrates issues of Idiopathic interstitial pneumonia, Interstitial pneumonia and Pneumonia in his study of Pathology. His Interstitial lung disease research incorporates elements of Arthritis, Scleroderma, Connective tissue disease, Hypersensitivity pneumonitis and Rheumatoid arthritis.
Kevin K. Brown mostly deals with Internal medicine, Idiopathic pulmonary fibrosis, Lung, Interstitial lung disease and Nintedanib. His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Placebo, Oncology and Cardiology. His biological study spans a wide range of topics, including Pulmonary fibrosis, Vital capacity and DLCO.
His Pulmonary fibrosis study is focused on Pathology in general. His work carried out in the field of Vital capacity brings together such families of science as Clinical trial and Intensive care medicine. The Interstitial lung disease study combines topics in areas such as Scleroderma, Connective tissue disease, Hypersensitivity pneumonitis and Rheumatology.
Kevin K. Brown spends much of his time researching Idiopathic pulmonary fibrosis, Internal medicine, Interstitial lung disease, FEV1/FVC ratio and Lung. His Idiopathic pulmonary fibrosis study combines topics in areas such as Vital capacity, DLCO, Gastroenterology, Gene and Lung biopsy. Kevin K. Brown has included themes like Immune dysregulation and Review article, Pathology in his DLCO study.
Internal medicine is often connected to Placebo in his work. His work on Usual interstitial pneumonia as part of general Interstitial lung disease study is frequently linked to Multidisciplinary approach, therefore connecting diverse disciplines of science. His Usual interstitial pneumonia study incorporates themes from Autoantibody and Rheumatoid arthritis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management
Ganesh Raghu;Harold R. Collard;Jim J. Egan;Fernando J. Martinez.
American Journal of Respiratory and Critical Care Medicine (2011)
American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias
William D. Travis;Talmadge E. King;Eric D. Bateman;David A. Lynch.
American Journal of Respiratory and Critical Care Medicine (2002)
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
Luca Richeldi;Roland M. du Bois;Ganesh Raghu;Arata Azuma.
The New England Journal of Medicine (2014)
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis;Ulrich Costabel;David M. Hansell;Talmadge E. King.
American Journal of Respiratory and Critical Care Medicine (2013)
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Harold R. Collard;Bethany B. Moore;Kevin R. Flaherty;Kevin K. Brown.
American Journal of Respiratory and Critical Care Medicine (2007)
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu;Martine Remy-Jardin;Jeffrey L. Myers;Luca Richeldi.
American Journal of Respiratory and Critical Care Medicine (2018)
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi;Ulrich Costabel;Moises Selman;Dong Soon Kim.
The New England Journal of Medicine (2011)
Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
Francis X. McCormack;Yoshikazu Inoue;Joel Moss;Lianne G. Singer.
The New England Journal of Medicine (2011)
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
Talmadge E. King;Jürgen Behr;Kevin K. Brown;Roland M. du Bois.
American Journal of Respiratory and Critical Care Medicine (2008)
A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis
Ganesh Raghu;Kevin K. Brown;Williamson Z. Bradford;Karen Starko.
The New England Journal of Medicine (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: